Celestra Inc. (KOSDAQ:352770)

South Korea flag South Korea · Delayed Price · Currency is KRW
5,250.00
-1,365.00 (-20.63%)
At close: Apr 3, 2025
Market Cap13.46B -82.8%
Revenue (ttm)5.61B -32.0%
Net Income-41.71B
EPS-19,368.55
Shares Out2.56M
PE Ration/a
Forward PEn/a
Dividendn/a
Ex-Dividend Daten/a
Volume320,768
Average Volume601,902
Open6,330.00
Previous Close6,615.00
Day's Range5,205.00 - 6,870.00
52-Week Range4,245.00 - 33,975.00
Beta1.11
RSI36.15
Earnings DateMar 20, 2026

About Celestra

Celestra Inc., a biotechnology company, provides genome-based cancer and disease diagnostic solutions. It provides TrioDx RT-PCR COVID-19 Test (FDA EUA), liquid biopsy and precision medicines, health care services, and big data solutions. The company’s liquid biopsy and precision medicines include CD-PRIME, a platform that offers automated protocols for the enrichment of circulating tumor cells (CTCs), cell free DNA, and EV (exosome) derived from cancer tissues; Cancer-PRIME, a cancer gene analysis service for analyzing results related to preci... [Read more]

Industry Medical Laboratories
Founded 2011
Employees 48
Stock Exchange KOSDAQ
Ticker Symbol 352770
Full Company Profile

Financial Performance

In 2024, Celestra's revenue was 8.50 billion, a decrease of -25.47% compared to the previous year's 11.41 billion. Losses were -46.92 billion, 11.0% more than in 2023.

Financial Statements